Kristian Reich, Chief Scientific Officer at MoonLake Immunotherapeutics (MLTX), sold 150,000 shares at $18.89 ($2.9M) on 2026-06-15, disclosed to the SEC on 2026-06-17.
Scheduled sale ($2.9M) by Chief Scientific Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $18.89 | 50,000 | $945K | 33.1% |
| 2 | $18.70 | 50,000 | $935K | 32.8% |
| 3 | $19.43 | 50,000 | $972K | 34.1% |
| Total | $19.01 avg | 150,000 | $2.9M | 100% |
| Filing → |
| MLTX | SELL | 2026-07-21 | $878K | — | Filing → |
| MLTX | SELL | 2026-07-20 | $322K | — | Filing → |
| MLTX | SELL | 2025-12-10 | $4.1M | — | Filing → |